Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.77)
# 4,012
Out of 5,090 analysts
58
Total ratings
34%
Success rate
-23.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Assumes: Buy | $11 | $5.87 | +87.39% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $24.14 | +28.42% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.42 | +1,240.86% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $8.85 | +137.42% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $5.59 | -10.47% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $2.44 | +557.08% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $1.54 | +7,692.21% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $25.51 | -1.98% | 2 | May 14, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $90.61 | - | 3 | Mar 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $2,000 | $5.01 | +39,820.16% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.29 | +442.64% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.87 | +158.40% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $16.55 | +262.54% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.75 | +241.92% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.42 | +192.02% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $1.79 | +13,345.38% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $3.42 | +5,221.64% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.27 | +29,485.80% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.18 | +379.04% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $12.93 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.15 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.27 | +164.32% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $6.74 | +211.57% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $18.78 | +55,810.54% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $4.65 | +695.70% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $57.50 | +421.78% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $722.83 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $100.48 | -11.43% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $153.75 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $15,000 | $0.90 | +1,675,690.41% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $2.04 | +16,411.06% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.34 | +314.75% | 1 | Mar 19, 2020 |
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $5.87
Upside: +87.39%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $24.14
Upside: +28.42%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.42
Upside: +1,240.86%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $8.85
Upside: +137.42%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $5.59
Upside: -10.47%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $2.44
Upside: +557.08%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $1.54
Upside: +7,692.21%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $25.51
Upside: -1.98%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $90.61
Upside: -
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $5.01
Upside: +39,820.16%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.29
Upside: +442.64%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $3.87
Upside: +158.40%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $16.55
Upside: +262.54%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.75
Upside: +241.92%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.42
Upside: +192.02%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $1.79
Upside: +13,345.38%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $3.42
Upside: +5,221.64%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.27
Upside: +29,485.80%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $4.18
Upside: +379.04%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $12.93
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.15
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $2.27
Upside: +164.32%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $6.74
Upside: +211.57%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $18.78
Upside: +55,810.54%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $4.65
Upside: +695.70%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $57.50
Upside: +421.78%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $722.83
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $100.48
Upside: -11.43%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $153.75
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $15,000
Current: $0.90
Upside: +1,675,690.41%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $2.04
Upside: +16,411.06%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $4.34
Upside: +314.75%